Home/Astellas/Hideo Ozawa

HO

Hideo Ozawa

Representative Director, Chair of the Board

Therapeutic Areas

Oncology Urology Immunology Ophthalmology Women's Health

Astellas Pipeline

Drug	Indication	Phase
Zolbetuximab	CLDN18.2-positive Gastric/GEJ Cancer	Regulatory Review
Enfortumab vedotin	Urothelial Carcinoma	Phase 3
AT845 (FORCE)	Late-Onset Pompe Disease	Phase 1/2
ASP2138	Solid Tumors	Phase 1
Gavocabtagene autoleucel	Autoimmune Diseases	Phase 1/2

Leadership Team at Astellas

Representative Director, President and CEO

Yoshitsugu Shitaka

Chief Scientific Officer (CScO)

Mark Reisenauer

President, Astellas Americas

Percival Barretto-Ko

President, Astellas Pharma Asia/Oceania

View full Astellas profile